Sirolimus 2% ( DrugBank: Sirolimus )

2 diseases

ID	Disease name (Link within this page)	Number of trials
36	Epidermolysis bullosa	2
192	Cockayne syndrome	2

36. Epidermolysis bullosa

Clinical trials : 163 / Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02960997 (ClinicalTrials.gov)	May 2016	15/6/2016	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Siroli ...	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus, 2%;Drug: Vehicle	Stanford University	NULL	Active, not recruiting	4 Years	N/A	All	8	Phase 2	United States
2	NCT03016715 (ClinicalTrials.gov)	May 2016	9/1/2017	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Siroli ...	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus 2%;Drug: Vehicle	Premier Specialists, Australia	NULL	Recruiting	5 Years	N/A	All	8	Phase 2	Australia

Clinical trials : 4 / Drugs : 7 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 51

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02960997 (ClinicalTrials.gov)	May 2016	15/6/2016	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Siroli ...	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus, 2%;Drug: Vehicle	Stanford University	NULL	Active, not recruiting	4 Years	N/A	All	8	Phase 2	United States
2	NCT03016715 (ClinicalTrials.gov)	May 2016	9/1/2017	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Siroli ...	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus 2%;Drug: Vehicle	Premier Specialists, Australia	NULL	Recruiting	5 Years	N/A	All	8	Phase 2	Australia